"In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.FST wasadministeredevery______ day.Our study showsthat blockingactivin signalingreduces ______production.Neutralizingantibodiestargetedactivin A and______.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________Enhanced NObioavailabilityindicatesimproved______.Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________Hypertension isdefined bysustained bloodpressure above____ mmHg.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.Whichhypertensiveanimal modeldid we use?___________The fluorescentproductproduced in theAmplexRedassay is called______.What is theendogenousprotein we studiedthat antagonizesactivin?_____________Follistatinmust maintainits proper______ to befunctional.What does theabbreviation'SHR' stand for? _____________Our assaydirectlymeasureshydrogen______ levels.FST lowersROS levels, asindicated by adecrease in______ levels.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.What assay didwe use toquantifyhydrogenperoxide?_____________Whichnormotensivestrain served asour control?_____________In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.Follistatin isknown toneutralizesignaling by______.FST’santioxidanteffect is lostif it is______.Follistatinretains itsantioxidanteffect evenwhen denatured.True/False"In our experiments,the reduction inoxidative stress wasmeasured as adecrease in the foldchange of ______.Follistatintreatmentreduced bloodpressure byapproximately______ mmHg.FST wasadministeredevery______ day.Our study showsthat blockingactivin signalingreduces ______production.Neutralizingantibodiestargetedactivin A and______.Which proteinmarker indicatesa brown adiposephenotype inPVAT?_____________Enhanced NObioavailabilityindicatesimproved______.Which type of assayis used to evaluateNO levels in ourstudy: fluorometricor colorimetric? _____________Hypertension isdefined bysustained bloodpressure above____ mmHg.Follistatintreatment induces______ of PVAT, aphenotypeassociated withimproved vascularfunction.Whichhypertensiveanimal modeldid we use?___________The fluorescentproductproduced in theAmplexRedassay is called______.What is theendogenousprotein we studiedthat antagonizesactivin?_____________Follistatinmust maintainits proper______ to befunctional.What does theabbreviation'SHR' stand for? _____________Our assaydirectlymeasureshydrogen______ levels.FST lowersROS levels, asindicated by adecrease in______ levels.Follistatinincreases theexpression of______, which iscritical for nitricoxide production.What assay didwe use toquantifyhydrogenperoxide?_____________Whichnormotensivestrain served asour control?_____________In our study,follistatin wasadministered toSHRs over aperiod of______ weeks.Follistatin isknown toneutralizesignaling by______.FST’santioxidanteffect is lostif it is______.Follistatinretains itsantioxidanteffect evenwhen denatured.True/False

Follistatin to the Rescue: Bingo for Lowering Pressure and Defeating ROS - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. "In our experiments, the reduction in oxidative stress was measured as a decrease in the fold change of ______.
  2. Follistatin treatment reduced blood pressure by approximately ______ mmHg.
  3. FST was administered every ______ day.
  4. Our study shows that blocking activin signaling reduces ______ production.
  5. Neutralizing antibodies targeted activin A and ______.
  6. Which protein marker indicates a brown adipose phenotype in PVAT? _____________
  7. Enhanced NO bioavailability indicates improved ______.
  8. Which type of assay is used to evaluate NO levels in our study: fluorometric or colorimetric? _____________
  9. Hypertension is defined by sustained blood pressure above ____ mmHg.
  10. Follistatin treatment induces ______ of PVAT, a phenotype associated with improved vascular function.
  11. Which hypertensive animal model did we use? ___________
  12. The fluorescent product produced in the AmplexRed assay is called ______.
  13. What is the endogenous protein we studied that antagonizes activin? _____________
  14. Follistatin must maintain its proper ______ to be functional.
  15. What does the abbreviation 'SHR' stand for? _____________
  16. Our assay directly measures hydrogen ______ levels.
  17. FST lowers ROS levels, as indicated by a decrease in ______ levels.
  18. Follistatin increases the expression of ______, which is critical for nitric oxide production.
  19. What assay did we use to quantify hydrogen peroxide? _____________
  20. Which normotensive strain served as our control? _____________
  21. In our study, follistatin was administered to SHRs over a period of ______ weeks.
  22. Follistatin is known to neutralize signaling by ______.
  23. FST’s antioxidant effect is lost if it is ______.
  24. Follistatin retains its antioxidant effect even when denatured. True/False